https://www.yiliao.com/index.php?action=history&feed=atom&title=NFKB1
NFKB1 - 版本历史
2026-04-18T18:21:50Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=NFKB1&diff=313153&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T02:39:35Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[核因子κB1]]([[NFKB1]])</strong>是一种关键的转录因子编码基因，属于<strong>[[NF-κB]]</strong>家族。该基因编码一个105kDa的蛋白质([[p105]])，经<strong>[[蛋白酶体]]</strong>加工后生成具有活性的50kDa亚基([[p50]])。[[NFKB1]]是调节免疫应答、炎症反应、细胞分化及抗凋亡程序的枢纽。在2026年的精准医学研究中，[[NFKB1]]的突变或表达异常被确认为<strong>[[普通变异型免疫缺陷病]]([[CVID]])</strong>及多种<strong>[[B细胞淋巴瘤]]</strong>的核心驱动因素。针对其下游通路进行的靶向干预已成为治疗难治性自身免疫病与血液肿瘤的重要策略。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">NFKB1</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Nuclear Factor Kappa B Subunit 1·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">NFKB1 p105/p50 Structure</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点基因：[[NFKB1]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">4790</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7794</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P19838</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">105kDa(前体)/50kDa(活性)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">染色体定位</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">4q24</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">蛋白家族</th><br />
<td style="padding: 12px; color: #1e40af;">[[Rel/NF-κB]]家族</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：经典信号通路的转换器</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[NFKB1]]在细胞内的活性状态取决于其从前体[[p105]]向活性亚基[[p50]]的有限蛋白水解加工。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>前体加工与抑制：</strong><br />
<br>[[p105]]的C端包含<strong>[[锚蛋白重复序列]]</strong>，能作为胞内抑制剂封锁[[NF-κB]]二聚体。当受到炎症信号(如[[TNF]]或[[IL-1]])刺激时，[[p105]]被磷酸化并介导<strong>[[泛素化]]</strong>降解。</li><br />
<li style="margin-bottom: 12px;"><strong>二聚化与转录激活：</strong><br />
<br>生成的[[p50]]与<strong>[[RelA]]([[p65]])</strong>结合形成异源二聚体。该复合物移位至细胞核，结合特定DNA序列，启动涉及<strong>[[细胞因子]]</strong>、<strong>[[粘附分子]]</strong>及细胞周期调节因子的基因转录。</li><br />
<li style="margin-bottom: 12px;"><strong>2026 发现更新：</strong><br />
<br>最新的结构生物学研究指出，[[p50]]同源二聚体在某些启动子上具有转录抑制作用，这种“双向调节”机制是维持免疫耐受的关键。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床病理关联与表型</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">病理/疾病类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">[[NFKB1]]的变异/异常(2026)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">普通变异型免疫缺陷病</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">单倍体不足(Haploinsufficiency)突变。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">表现为低丙种球蛋白血症及严重的自身免疫病倾向。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">弥漫大B细胞淋巴瘤</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">基因扩增或下游通路持续激活。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[NF-κB抑制剂]]</strong>联合化疗的适应指征。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">慢性阻塞性肺疾病</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">气道上皮细胞中[[NFKB1]]过表达。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">驱动持续性粘液分泌及慢性炎症。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗干预策略</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对[[NFKB1]]及其通路的治疗已进入高度精准化阶段：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[蛋白酶体抑制剂]]应用：</strong>如<strong>[[凯普利]]([[卡非佐米]])</strong>通过阻断[[p105]]的加工，间接抑制[[p50]]的生成，是治疗[[NFKB1]]依赖型骨髓瘤的基石。</li><br />
<li style="margin-bottom: 12px;"><strong>[[IKK复合体]]抑制剂：</strong>新型小分子旨在特异性阻断[[p105]]的磷酸化，从而在不影响基底代谢的情况下平息过度的免疫反应。</li><br />
<li style="margin-bottom: 12px;"><strong>[[PROTAC]]降解技术：</strong>针对淋巴瘤中过度稳定的活性亚基，2026年已有进入临床阶段的靶向[[p50]]降解剂，实现了更彻底的信号沉默。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[NFKB2]]：</strong>非经典信号通路的核心成员，与[[NFKB1]]共同维持转录平衡。</li><br />
<li style="margin-bottom: 8px;"><strong>[[RelA]]([[p65]])：</strong>[[p50]]最主要的异源二聚体伙伴，负责强效的转录激活。</li><br />
<li style="margin-bottom: 8px;"><strong>[[RHD结构域]]：</strong>[[NF-κB]]家族共有的DNA结合及二聚化结构模块。</li><br />
<li style="margin-bottom: 8px;"><strong>[[TRAF家族]]：</strong>位于[[NFKB1]]上游，负责传递受体端的激活指令。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Karin M,et al.(2000/2025Revision).</strong> <em>NF-κB in health and disease:A 25-year retrospective on NFKB1 signaling.</em> <strong>[[Nature Reviews Immunology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：该综述精辟解析了[[NFKB1]]前体加工的时空特异性，为理解复杂炎症性疾病提供了分子框架。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Lorenzini T,et al.(2024Update).</strong> <em>NFKB1 haploinsufficiency:The expanding clinical spectrum of primary immunodeficiency.</em> <strong>[[Journal of Allergy and Clinical Immunology]]</strong>.<br><br />
<span style="color: #475569;">[学术点评]：2026年最新的临床数据强调了[[NFKB1]]单倍体不足在成人起病型免疫缺陷中的普遍性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
核因子κB1(NFKB1)·知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联亚基</td><br />
<td style="padding: 10px 15px; color: #334155;">[[RelA]]•[[RelB]]•[[c-Rel]]•[[p105]]•[[p50]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">激活酶系</td><br />
<td style="padding: 10px 15px; color: #334155;">[[IKKα]]•[[IKKβ]]•[[IKKγ]]•[[NIK]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">干预靶向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[20S蛋白酶体]]•[[JAK2抑制剂]]•[[Bcl-2抑制剂]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">疾病领域</td><br />
<td style="padding: 10px 15px; color: #334155;">[[自身免疫病]]•[[原发性免疫缺陷]]•[[恶性淋巴瘤]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166